Robert Peach
Follow
Get notifications in MyBN when activity occurs.
Robert Peach
Non-Executive Director / Amplia Therapeutics
Dr Robert Peach has over 25 years of drug discovery and development experience in the pharmaceutical and biotechnology industry.
In 2009, Dr Peach co-founded Receptos and became chief scientific officer, raising $59M in venture capital and $800M in an IPO and three subsequent follow-on offerings. In August 2015 Receptos was acquired by Celgene for $7.8B.
Dr Peach held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb where he supported in-licensing, acquisition and venture investments.
His extensive drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs. He is also the co-author of 70 scientific publications and book chapters, and 17 patents.
In 2009, Dr Peach co-founded Receptos and became chief scientific officer, raising $59M in venture capital and $800M in an IPO and three subsequent follow-on offerings. In August 2015 Receptos was acquired by Celgene for $7.8B.
Dr Peach held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb where he supported in-licensing, acquisition and venture investments.
His extensive drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs. He is also the co-author of 70 scientific publications and book chapters, and 17 patents.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 23rd | Gold Hydrogen | 255% | |
| 906th | Amplia Therapeutics | -12% | -8% |
| 1135th | Odyssey Gold | -28% | -16% |
| 1199th | Mindax | -32% | 46% |
| 1696th | Cobalt Blue Holdings | -67% | -3% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 993rd |  | Amplia Therapeutics | $1.2m |
| 1255th | | Odyssey Gold | $0 |
| 1257th | | Gold Hydrogen | $0 |
| 1259th | | Cobalt Blue Holdings | $0 |
| 1260th | | Mindax | $0 |
1328 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEW ROLE: Non-Executive Director, Amplia Therapeutics | 19 Apr 2021 |
